论文部分内容阅读
目的探讨羟自由基清除剂依达拉奉(必存)治疗急性脑梗死患者的临床疗效。方法将60例急性脑卒中病人随机分为治疗组与对照组各30例,两组均用欣易通治疗,治疗组加用必存,对照组加用胞磷胆碱。两组病人分别在入院时、3周后及3月后进行 Bathel 指数(BI)总分及日常生活活动能力(ADL)积分的评定并进行比较。结果治疗组在3周时(P<0.05)及3月时(P<0.01)BI 总分改善方面均优于对照组,3月时两组的有效率分别为86.67%和76.67%,治疗组更佳(P<0.05),在 ADL改善方面,治疗组亦明显优于对照组(P<0.05)。结论必存对急性缺血性卒中患者有一定疗效。
Objective To investigate the clinical efficacy of edaravone (essential preservative) scavenger of hydroxy radical scavenger in patients with acute cerebral infarction. Methods Sixty patients with acute stroke were randomly divided into treatment group (30 cases) and control group (30 cases). Both groups were treated with XHT. The treatment group and the control group were given citicoline. Two groups of patients were assessed on the Bathel index (BI) score and ADL score at 3, 3 and 3 months after admission, and compared. Results The improvement of the total score of BI in the treatment group was better than that of the control group at 3 weeks (P <0.05) and 3 months (P <0.01). The effective rates of the two groups were 86.67% and 76.67% (P <0.05). In ADL improvement, the treatment group was also significantly better than the control group (P <0.05). Conclusions Must exist in patients with acute ischemic stroke have a certain effect.